Pancreatic cancer kills roughly seven of every eight Americans who get it within five years. About 67,000 people are diagnosed each year. For decades, nothing moved that number much.
Something moved it. The FDA cleared Revolution Medicines’ Rasonque, known in trials as daraxonrasib. Median survival went to 13.2 months from 6.7 on chemotherapy, and the risk of death fell 60%.
What the drug does
Most pancreatic tumors are driven by a family of proteins called RAS. RAS has been known as a cancer driver since the 1980s and was considered undruggable for most of that time, because its surface offers almost nothing for a molecule to grab.
This drug grabs it. That is the whole scientific headline, and it took forty years.
| The trial | New treatment | Chemotherapy |
|---|---|---|
| Median survival | 13.2 months | 6.7 months |
| Reduction in risk of death | 60% | — |
| Monthly cost | $39,800 | — |
| Annual cost | $477,000+ | — |
Median is a word worth defining
Median survival means half the patients lived longer than that and half did not. It is not a promise to any individual.
Some patients in the trial did far better than 13.2 months. Some did worse. What the number tells you is that the whole distribution moved right, which in this disease had not happened in a long time.
The price, said out loud
Rasonque lists at $39,800 a month. That is more than $477,000 a year. Analysts think it becomes a $20 billion-a-year product.
Insurance will cover most of it for most patients, and the coinsurance on a $477,000 drug is still a serious number. Medicare Part D now caps annual out-of-pocket drug spending, which matters enormously here, but the cap does not cover everything a cancer year costs.
This is the shape of modern oncology. The medicine arrives, and the family arrives at a benefits office.
The other half of the story is a scan
Stage-four pancreatic cancer has a five-year survival rate of about 3%. Caught early, that figure rises toward 40%.
Almost nobody catches it early, because the pancreas sits deep in the abdomen and the symptoms are vague until they are not.
Mayo Clinic has built an artificial-intelligence model that reads ordinary CT scans and flags the disease up to three years before a radiologist would. Nothing new is scanned. The model simply sees what was already in images taken for other reasons.
If that tool scales, it may end up mattering more than the drug. Turning a 3% survival rate into a 40% one beats extending a terminal course by six months, and it costs far less.
How we hold this as investors
Revolution Medicines shares rose 2% on the approval, which is a modest move for an approval this significant. Markets had largely priced the trial results already.
We are watching, not buying. A company whose value rests on one approved drug is a binary bet, and binary bets do not belong in a portfolio built to fund retirements.
The broader lesson is the planning one. Treatments that cost more than a house are now normal, and the households that handle them best are the ones who understood their coverage before the diagnosis, not after.